Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 2
Submit an article Journal homepage
693
Views
13
CrossRef citations to date
0
Altmetric
Letters to the Editor

The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a “real-world” study: the Royal Marsden Hospital experience

Priya Sriskandarajaha Department of Haemato-Oncology, Royal Marsden Hospital, Sutton, UK;b The Institute of Cancer Research, London, UK
,
Charlotte Pawlyna Department of Haemato-Oncology, Royal Marsden Hospital, Sutton, UK;b The Institute of Cancer Research, London, UK
,
Kabir Mohammeda Department of Haemato-Oncology, Royal Marsden Hospital, Sutton, UK
,
Claire E. Deardena Department of Haemato-Oncology, Royal Marsden Hospital, Sutton, UK
,
Faith E. Daviesa Department of Haemato-Oncology, Royal Marsden Hospital, Sutton, UK;c Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
,
Gareth J. Morgana Department of Haemato-Oncology, Royal Marsden Hospital, Sutton, UK;c Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
,
Kevin D. Boyda Department of Haemato-Oncology, Royal Marsden Hospital, Sutton, UK
&
Martin F. Kaisera Department of Haemato-Oncology, Royal Marsden Hospital, Sutton, UK;b The Institute of Cancer Research, London, UKCorrespondence[email protected]
 show all
Pages 494-497 | Received 10 Mar 2016, Accepted 01 Jun 2016, Published online: 20 Jul 2016

References

  • Richardson PG, Siegel DS, Hofmeister CC, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123:1826–1832.
  • Kumar SK, Lee JH Lahuerta JJ. International Myeloma Working Group, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and Bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149–157.
  • Fionda C, Abruzzese MP, Zingoni A, et al. The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. Oncotarget. 2015;6:23609–23630.
  • San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory myeloma (MM-003): a randomized, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–1066.
  • Gras J. Pomalidomide for patients with multiple myeloma. Drugs Today (Barc). 2013;49:555–562.
  • Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473.
  • Bird JM, Owen RG, D’Sa S.; on behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology (BCSH), UK Myeloma Forum, et al. Guidelines for the diagnosis and management of multiple myeloma. BCSH Guidelines. 2014;1–99.
  • Dimopoulos MA, Palumbo A, Corradini P, et al. The STRATUS (MM-010) Trial: a single-arm, phase 3b study evaluating safety and efficacy of pomalidomide + low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma [abstract]. European Hematology Association Congress 2015;100S1:83(P273).
  • Dimopoulos MA, Leleu X, Palumbo A, et al. Expert panel consensus statement on the optimal use of Pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28:1573–1585.
  • Morgan G, Palumbo A, Dhanasiri S, et al. Overall survival of relapsed an refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. Br J Haematol 2015;168:820–823.
  • Dimopoulos MA, Weisel KC, Song KW, et al. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica. 2015;100:1327–1333.
  • Boyd KD, Ross FM Walker BA. NCRI Haematology Oncology Studies Group, et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res. 2011;17:7776–7784.
  • Boyd KD, Ross FM, Chiecchio L, et al. and NCRI Haematology Oncology Studies Group. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26:349–355.
  • Fouquet G, Pegourie B, Macro M, et al. IFM (Intergroupe Francophone du Myelome), et al. ‘Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma. Ann Oncol. 2016;27:902–907.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.